SAM, Goodwin, Saraf, Cravath advise on $3.34 bln biopharma deal
BY Mari Iwata |
Shardul Amarchand Mangaldas & Co. and Goodwin Procter have advised Biocon Biologics, a subsidiary of Indian drugmaker Biocon, in its $3.34 billion acquisition of the biosimilars business of U.S.-based Viatris, which was counseled by Cravath, Swaine & Moore, and Saraf and Partners.